Aro Biotherapeutics

This is the first human study testing ABX1100, a new drug for late-onset Pompe disease—a rare genetic disorder that weakens muscles. Researchers will check the safety of different doses in 46 healthy volunteers and patients with the disease. The study will measure how the drug mo…